GlassScriptPhysician profile
Peter Andrew Sweeny
NPI 1861811770
$2,833.03
in general payments reported to CMS, 2019-2025
12 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 77% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $22.59 · 2021: $268 · 2022: $13.86 · 2023: $639 · 2024: $162 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556 · Travel and Lodging: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.58 |
| Travel and Lodging | $723.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,056.26 | 2024-2025 | Progrip, Transorb, Venaseal |
| Intuitive Surgical, INC. | $598.96 | 2020-2024 | Da Vinci Surgical System |
| Baxter Healthcare | $307.49 | 2023-2025 | Floseal |
| Davol INC. | $235.54 | 2023-2025 | Phasix Mesh, Arista Ah Flexitip |
| Coopersurgical, INC. | $127.59 | 2019 | |
| Ethicon US, LLC | $114.22 | 2023-2024 | Surgicel Nu-Knit, Stratafix, Echelon; Endopath |
| Teleflex LLC | $113.62 | 2025 | Titan Sgs Bailout Chuck |
| Innovation Technologies INC | $93.46 | 2025 | Irrisept |
| Janssen Pharmaceuticals, INC | $80.48 | 2019 | |
| Lemaitre Vascular, INC. | $45.73 | 2021-2023 | Artegraft Vascular Graft |
| Tei Biosciences INC | $41.46 | 2019 | |
| Solventum Corporation | $18.22 | 2024 | Activ.A.C. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sweeny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.